kleisin β Inhibitors

Kleisin β inhibitors comprise a chemical class designed to interfere with the function of kleisin β, a subunit within the cohesin complex responsible for sister chromatid cohesion during cell division. These inhibitors work by targeting various proteins and pathways that regulate or interact with kleisin β and the cohesin complex. The cohesin complex has an essential role in maintaining genomic stability, and any alteration in its function can result in defective chromosome segregation.

Inhibitors such as ATR kinase inhibitor (VE-821) and CDK1 inhibitor (RO-3306) function by disrupting the activity of kinases crucial for regulatory phosphorylation events within the cell cycle. Such disruptions can lead to altered cohesin function and the subsequent indirect inhibition of kleisin β. The PLK1 inhibitor (BI 2536) and Aurora B kinase inhibitor (ZM447439) target kinases that are directly involved in the regulation of both cohesin placement on chromosomes and its removal during cell division. Chloroquine, while not a direct inhibitor of WAPL, can interfere with endosomal pathways that indirectly influence WAPL function, affecting cohesin complex dynamics. kleisin β inhibitors affect various biological targets, including kinases, enzymes and protein complexes involved in the regulation of cell cycle and chromosome segregation, where kleisin β plays a crucial role. These compounds leverage the interconnected nature of cellular signaling pathways to exert their influence on kleisin β indirectly. By inhibiting the activity or stability of proteins that regulate the cohesin complex, of which kleisin β is a component, these compounds can alter the dynamics of chromosome cohesion and separation.